Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone

Calcified Tissue International

Volumn 60, Issue 5, 1997, Pages 415-418

  Arden Cordone, M ^a   Siris, E S ^a   Lyles, K W ^b,c   Knieriem, A ^a   Newton, R A ^b   Schaffer, V ^d   Zelenakas, K ^d  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bisphosphonates; Bone resorption; Paget's disease of bone Hydroxyproline; Serum alkaline phosphatase; Zoledronate

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CREATININE; HYDROXYPROLINE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CREATININE URINE LEVEL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE RESORPTION; CALCIUM; CREATININE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROXYPROLINE; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; OSTEITIS DEFORMANS;

EID: 0030896159     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002239900255     Document Type: Article

References (13)

1. Canfield RE, Rosner W, Skinner J et al (1977) Diphosphonate therapy of Paget's disease of bone. J Clin Endocrinol Metab 44:96-106
2. Harinck HIJ, Papapoulos SE, Blanksma HJ et al (1987) Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidine bisphosphonate (APD). Br Med J 295:1301-1305
3. Douglas DL, Kanis JA, Duckworth T et al (1981) Paget's disease: improvement of spinal cord dysfunction with diphosphonates and calcitonin. Metab Bone Dis Rel Res 3:327-336
4. Adami S, Mian M, Gatti P et al (1994) Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 15:415-417
5. Reginster JY, Treves R, Renier JC et al (1994) Efficacy and tolerabihty of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone. J Bone Miner Res 9:615-619
6. Green JR, Muller K, Jaeggi KA (1994) Preclinical pharmacology of CGP 42446, a new potent heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751
7. Heynen G, Delwaide P, Bijvoet OLM et al (1982) Clinical and biological effects of low doses of (3-amino-l-hydroxypropy-lidine)-1, 1 bisphosphonate (APD) in Paget's disease of bone Eur J Clin Invest 11:29-35
8. O'Doherty DP, Bickerstaff DR, McCloskey EV et al (1990) The treatment of Paget's disease of bone with aminohydroxy-butylidine bisphosphonate. J Bone Miner Res 5:483-491
9. Thiebaud D, Jaeger P, Gobelet C et al (1988) A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 85:207-212
10. Siris ES (1994) Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease. J Bone Miner Res 9:303-304
11. Schaffer AV, Buckler H, Ryan W, Richardson P (1996) A double-blind placebo-controlled trial using intravenous zoledronate (CGP 42446) in patients with Paget's disease of bone. J Bone Miner Res 11 (suppl 1):S373
12. Kanis J (1991) Pathophysiology and treatment of Paget's disease of bone. Carolina Academic Press, Durham. NC pp 192-204
13. Adamson BB, Gallacher SJ, Byars J et al (1993) Mineralisation detects with pamidronate therapy for Paaet's disease Lancet 342:1459-1460